Edition:
United States

BioTime Inc (BTX.A)

BTX.A on American Stock Exchange

2.97USD
21 Jul 2017
Change (% chg)

$0.03 (+1.02%)
Prev Close
$2.94
Open
$3.01
Day's High
$3.04
Day's Low
$2.96
Volume
79,000
Avg. Vol
66,036
52-wk High
$4.00
52-wk Low
$2.70

BTX.A

Chart for BTX.A

About

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $329.30
Shares Outstanding(Mil.): 110.88
Dividend: --
Yield (%): --

Financials

  BTX.A Industry Sector
P/E (TTM): 3.05 213.75 15.85
EPS (TTM): 0.97 -- --
ROI: 84.66 -7.93 -8.31
ROE: 100.87 -9.29 -7.95

BRIEF-Biotome: Opregen trial data to be presented at 2017 AAO meeting

* Data from Biotime’S Phase I/IIA Opregen trial to be presented at the 2017 American Academy Of Ophthalmology (AAO) annual meeting Source text for Eikon: Further company coverage:

Jul 19 2017

BRIEF-Biotime unit Agex Therapeutics appoints Aubrey De Grey as VP of new technology discovery

* Biotime subsidiary Agex Therapeutics appoints Aubrey De Grey, PH.D. as vp of new technology discovery Source text for Eikon: Further company coverage:

Jul 13 2017

BRIEF-Biotime files for possible resale of up to 4.92 mln shares of co's common stock

* Biotime Inc files for possible resale of up to 4.92 million shares of co's common stock, no par value per share, by selling shareholders - sec filing Source text for Eikon: Further company coverage:

Jun 16 2017

BioTime's Renevia succeeds in pivotal European facial wasting trial

BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year.

Jun 14 2017

BioTime's Renevia succeeds in pivotal European facial wasting trial

BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year.

Jun 14 2017

BioTime's Renevia succeeds in pivotal European facial wasting trial

June 14 BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year.

Jun 14 2017

BRIEF-Biotime reports Q1 earnings per share $0.46

* Reports first quarter results and recent corporate accomplishments

May 10 2017

BRIEF-Biotime Inc enters into a controlled equity offering sales agreement with Cantor Fitzgerald & Co

* Biotime Inc- on April 6, co entered into a controlled equity offering sales agreement with cantor Fitzgerald & Co as sales agent

Apr 11 2017

BRIEF-BioTime files for mixed shelf of up to $75 mln

* Files for mixed shelf of up to $75 mln -SEC filing Source text: [http://bit.ly/2p6N2l5] Further company coverage:

Apr 06 2017

BRIEF-Biotime qtrly loss per share $0.05

* Biotime, Inc. Reports fourth quarter and fiscal year 2016 financial results and recent corporate accomplishments

Mar 16 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €81.52 -1.25
Baxter International Inc (BAX.N) $62.67 -0.37
Hospira, Inc. (HSP.N) -- --

Earnings vs. Estimates